Osteoarthritis (OA) is the most common form of arthritis, affecting more than 1 in 8 Canadians. 1 With an aging population, the prevalence of OA in Canada is rising. From 2010 to 2031, the prevalence of OA is projected to increase from 13.8% to 18.6%, with the total direct costs projected to increase from $2.9 billion to $7.6 billion, an almost 2.6-fold increase. 2 OA has traditionally been thought to be a progressive disease of the synovial joints that is due to daily "wear and tear" from excessive and repetitive force on joint cartilage. While this is partially true, OA is now believed to be a systemic disorder due to an imbalance between joint destruction and repair. [3] [4] [5] [6] The result is a breakdown of cartilage and bone, leading to symptoms of pain, stiffness and functional disability.
The joints most commonly affected by OA (in order of prevalence) are the hands, knees, hips and spine. OA is more prevalent with age, affecting nearly half the population older than 70. 3 In addition to advancing age, female gender is a significant risk factor. Other risk factors include obesity, quadriceps muscle weakness, family history, joint injury and joint overuse or injury (e.g., participation in certain sports). 3, 7 Evidence for pharmacist care in OA Pharmacists are frontline, accessible health care professionals who see patients 5 times more frequently than family physicians. 8 Community pharmacists have proven they can address gaps in OA patient care. Many people with OA are not diagnosed and are not referred for treatment. Pharmacists are ideally placed to screen for OA and make treatment recommendations, as they are often consulted about the choice of over-thecounter (OTC) analgesics to manage OA pain.
Research conducted in Canadian pharmacies has shown that pharmacists can effectively screen for OA. Community pharmacists in Edmonton and Vancouver, using a simple screening questionnaire (<10 minutes to complete), identified >80% of patients with knee pain who had undiagnosed knee OA. 9 Within 6 months of receiving their diagnosis, >90% of participants had visited their family physician to discuss their OA, >50% took either a prescription or nonprescription analgesic and a significant number (p < 0.001 for all) of patients saw improvements in their pain, function and daily activity scores. 10 Canadian pharmacists have also effectively launched multidisciplinary interventions to improve health outcomes for patients with undiagnosed knee OA. 11 Patients who reported knee pain at community pharmacies in Vancouver were effectively screened for OA and assigned to either "usual care" (i.e., provided with a pamphlet on knee OA created by the Arthritis Society) or "intervention care" (i.e., one-on-one consultation where the pharmacist offered arthritis education, medication reviews and referral to a physiotherapist-guided exercise program). Outcomes from the pharmacistpatient consultation were recorded and faxed to the patient's primary care physician. Compared to "usual care, " significantly more patients in the intervention group noted improvements in their quality of care and significant improvements in global, pain and functional scales. This evidence, combined with the expanding role of the pharmacist across the country, ideally positions pharmacists to improve the care of patients with OA.
The following recommendations are made with input from a number of OA treatment guideline documents, as applicable to pharmacists. [12] [13] [14] [15] [16] Practice guidelines
What should a pharmacist do? Recommendations for pharmacist interventions 1. Screen for OA
• Figure 1 illustrates the approach a pharmacist should take when assessing a patient presenting for selfmanagement with either new-onset joint pain or a diagnosis of OA. 
Principles of therapy
The goal of OA therapy is to relieve symptoms of pain, improve joint function and mobility and improve quality of life while minimizing medication-related adverse events. Pharmacists can educate patients and caregivers to help them understand their condition and work with both the patients and their primary health care provider to choose an appropriate therapy. Current nonpharmacological BOX 1 Levels of evidence
We have chosen to follow the Osteoarthritis Research Society International (OARSI) criteria for summarizing the strength of the available literature for each recommendation. 12 Meta-analyses, systematic reviews (SRs) and randomized control trials (RCTs) are considered the highest level of evidence. The quality and level of evidence are described by OARSI as follows:
Level/type of evidence: The highest level of evidence available at this time (e.g., meta-analysis or most current RCT).
Quality of evidence:
Meta-analyses and SRs were assigned a quality rating of "good, " "fair" or "poor" according to the Assessment of Multiple Systematic Reviews Tool (AMSTAR). The Cochrane Risk of Bias Assessment Method was used to rate RCTs. In instances where no new evidence existed, we used the quality of evidence rating as assigned by OARSI. Where new evidence existed, our quality ratings were assigned based on AMSTAR total score: 8 to 11 was considered "good, " 5 to 7 was considered "fair, " and 0 to 4 was considered "poor. "
PRaCtiCeguideLiNes and pharmacological treatment options for OA provide symptom relief, but they are not curative and do not slow progression of OA. 3 Choice of treatment is typically based on risk versus benefit, cost and patient preference. Pharmacological treatment options should always be used in combination with nonpharmacological options (Figure 2 ). Generally therapies should be tried for at least 1 to 2 weeks to allow for adequate assessment of effectiveness. 3
Nonpharmacological treatment options
Nonpharmacologic therapies are important in OA and are supported by varying levels of evidence for safety and efficacy. These modalities should always be tried first or initiated at the same time as drug therapy. 3, [12] [13] [14] The role of the pharmacist in the nonpharmacological treatment of OA is mainly to recognize the need for referral to other health care professionals and Practice guidelines ensure the patient has access to appropriate specialized care.
Nonpharmacological therapies with the most evidence for benefit and the greatest consensus from guidelines include patient education for self-management, [17] [18] [19] [20] [21] [22] [23] [24] land-and water-based exercise [25] [26] [27] [28] [29] [30] [31] and weight loss. 32, 33 Supports and braces 34, 35 may also offer pain relief and improved function, while those with knee OA may benefit from corrective footwear. [35] [36] [37] [38] [39] Patients who wish to incorporate these therapies into their OA management can be referred to a dietitian, physiotherapist or occupational therapist as appropriate. Those with knee OA may also benefit from the use of assistive walking devices such as canes 39, 40 or walkers or transcutaneous PRaCtiCeguideLiNes electrical nerve stimulation (TENS) devices. [41] [42] [43] Corrective footwear can reduce pain and medication use in knee OA by redistributing the balance of weight-bearing pressures in the foot. 43, 44 Use of TENS has been shown to reduce pain and stiffness. 41, 42 Acupuncture, 45 heat, cold 46 and massage may also reduce pain and stiffness in those with knee OA. Nonpharmacological therapies with limited evidence are not recommended; these include balneotherapy (bathing in mineral springs), 47-50 ultrasound 51,52 and electrotherapy. 53,54
Pharmacological treatment options
Natural health products Due to a lack of evidence for efficacy, published guidelines are in agreement regarding therapy with the 2 most popular natural health products for osteoarthritis, and all recommend against the use of glucosamine or chondroitin for OA. [12] [13] [14] These agents are generally considered safe, with few drug interactions, although glucosamine and chondroitin can potentiate the anticoagulant effects of warfarin. 55 Taking glucosamine/ chondroitin together with warfarin should be avoided if possible; otherwise, patients will initially require more frequent monitoring of their international normalized ratio (INR) and should be counselled on signs of increased warfarin effects (e.g., bruising, bleed). Patients wishing to try them may do so, although we encourage Practice guidelines setting a date to reassess efficacy. Other natural products that patients may request include S-adenosyl-L-methionine, methylsulfonylmethane, Indian frankincense, avocado soybean unsaponifiables, shark cartilage and rose hip, although there is little high-quality evidence for their efficacy in OA. [12] [13] [14] Topical therapy
Capsaicin. Capsaicin depletes substance P, thus reducing the pain the patient experiences, and has been found to be both moderately effective in reducing pain up to 20 weeks and generally is well tolerated. 56 Capsaicin does not have an official indication for OA. Zucapsaicin is the cis isomer of capsaicin and is indicated in those with knee OA pain not controlled by either oral nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors alone. Either capsaicin or zucapsaicin may be considered an adjunct to oral therapy in knee or hand OA. 3, [57] [58] [59] [60] The maximum therapeutic effect may not be seen until 4 weeks with regular administration (3-4 times daily). 3 Topical NSAIDs. NSAIDs are available topically in multiple dosage forms, including both a gel and a topical solution. All OA guidelines recommend the use of topical NSAIDs for the treatment of OA pain of either the hand or knee, although no recommendations are made regarding hip OA. [12] [13] [14] The only official indication for topical NSAIDs in OA is for diclofenac sodium solution for knee OA. 61 The maximum therapeutic effect may not be seen until 2 weeks of regular administration (3-4 times daily). 3 Acetaminophen Acetaminophen continues to be recommended as the initial drug of choice for treatment of OA. [12] [13] [14] [15] [16] The rationale for using acetaminophen is largely based on the fact that acetaminophen is effective, relatively safe, well tolerated and easily accessible. 3 Evidence suggests that short-term use of acetaminophen has a low to moderate effect on OA pain. 12, 62, 63 Newer evidence suggests that acetaminophen may be less effective and has greater risks than previously thought. 3, 12, 64, 65 The U.S. Food and Drug Administration has recommended that all products containing acetaminophen be limited to 325 mg per dosage unit, 22 while Health Canada is assessing whether similar changes be made in Canada. 23 Patients taking acetaminophen should be counselled not to exceed the daily maximum dose and to consider acetaminophen from all sources (i.e., OTC and prescription products).
Typically, studies use the maximum daily dose of acetaminophen (1 gram 4 times daily) for a short period of time (median 6 weeks). 63 PRaCtiCeguideLiNes therapeutic doses should be used for 2 weeks to assess efficacy, then use the lowest effective dose. Risk of hepatotoxicity may be increased in the elderly and those with excessive alcohol intake (>3 drinks per day) or liver disease. These are not contraindications to therapy, but some experts recommend dosage reductions (elderly: maximum dose 3200 mg/day; alcohol use/preexisting hepatotoxicity: maximum dose 2600 mg/day). 66 
NSAIDs
Due to the risk of serious adverse effects, NSAIDs are generally reserved for treatment after failure of acetaminophen in the management of OA pain. [12] [13] [14] [15] [16] Although acetaminophen is considered a safer option, NSAIDs are often preferred by patients due to improved pain relief. 3, 67, 68 Generally, it is reasonable to consider initiating topical NSAID therapy before starting therapy with oral NSAIDs, particularly in elderly patients. 69 Prior to starting NSAID therapy, patients must be assessed for their risk of cardiovascular, gastrointestinal and renal complications (see Table 1 ). All NSAIDs demonstrate an increased risk of thromboembolic events (e.g., myocardial infarction [MI] or stroke). 3, 61 This increase in risk, while concerning, is much smaller when compared to traditional risk factors such as high blood pressure and smoking. Studies suggest that the risk of cardiovascular events is highest with diclofenac, celecoxib and high-dose ibuprofen. Naproxen has been found to have the lowest risk of cardiovascular events. [70] [71] [72] [73] Health Canada advises that NSAIDs be used with caution in patients with cardiovascular risk factors and recommends that they be used at the lowest effective dose for the shortest period of time. 74 If treatment with an NSAID is essential, patients at increased risk of cardiovascular complications (see Table 1 ) should be treated with naproxen (and with low-dose acetylsalicylic acid [ASA], if indicated for cardiovascular protection). 12 All NSAIDs can increase blood pressure and worsen preexisting hypertension; therefore, baseline and periodic monitoring of blood pressure is necessary. When starting NSAIDs in patients on antihypertensive therapy, reevaluate the patients' blood pressure in 1 week to determine whether dosage changes are needed to either the NSAID or the antihypertensive. 3 NSAIDs can irritate the stomach (bloating, nausea, heartburn, etc.), so patients should be encouraged to take them with food. While dyspepsia has been reported in up to 60% of patients, the actual incidence is likely close to 5% to 10%. 75 RAs). Serious GI complications (e.g., perforated ulcers, hemorrhage) are estimated to occur at an incidence of less than 1% per year. 76 Celecoxib is as effective as the nonselective NSAIDs and is associated with a lower incidence of gastrointestinal ulcers. 77 However, this reduced risk is modest and may not extend past 6 months of therapy. Prior to starting therapy, identify patients at risk of gastrointestinal complications and take preventative measures ( Table 1 and Figure 2) . Either misoprostol or proton pump inhibitors (e.g., omeprazole) are the recommended options for preventing serious GI complications in patients at risk of NSAID-induced ulcer. [76] [77] [78] However, misoprostol is generally not well tolerated, the most common adverse effects being abdominal pain and diarrhea. H 2 RAs and antacids do not provide protection against serious NSAID-induced GI complications and should not be recommended for this indication.
All NSAIDs increase the risk of impaired renal function and can cause acute kidney injury, especially when added to antihypertensives like diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers. 79, 80 NSAIDs should be avoided in patients with severe renal impairment (creatinine clearance [CrCl] <30 mL/min), and their prolonged use is generally not recommended in those with mild to moderate renal impairment. 61 Patients who take medications that affect renal function or those who have underlying renal dysfunction should have their renal function reevaluated 7 to 10 days after starting NSAID therapy and periodically thereafter.
Opioids and tramadol
Opioids: transdermal. Given the limited ability to titrate doses using transdermal opioid formulations and the paucity of evidence for the use of opioids in general, these formulations are not ideal for the treatment of OA pain and should be avoided. 81 Opioids: oral. The evidence is conflicting when it comes to the use of opioids to treat pain associated with OA. [12] [13] [14] While studies have found small statistically significant improvements in pain with codeine over placebo, patients taking opioids were 4 times more likely to withdraw due to adverse effects. 12 The evidence for opioid analgesia in OA is poor and there remains significant concern about toxicity. 14 We recommend reserving opioids as a last-line option, particularly for short-term pain control for those awaiting surgical intervention.
Tramadol. Tramadol has demonstrated limited efficacy in the treatment of OA. 12 Guidelines conditionally recommend the use of tramadol for hand, knee and hip OA, especially in those 75 years of age or older. 13 The combination of tramadol and acetaminophen may pose additional risks for acetaminophen toxicity in those patients taking other acetaminophen products or at otherwise increased risk of toxicity. We recommend reserving tramadol as a last-line option, as the beneficial effects are often outweighed by its increased risk of adverse events.
Duloxetine
Currently available evidence for use of duloxetine in OA is limited and restricted to OA of the knee. A 13-week RCT in knee OA showed positive effects of duloxetine on both pain (number needed to treat [NNT] = 6) and physical function (NNT = 9) with no increase in serious adverse events but significantly more treatmentemergent adverse effects compared to placebo. 82 A second RCT found that the addition of duloxetine to optimized NSAID therapy provided significantly greater pain reduction and functional improvement compared to placebo. 83 A 2012 systematic review comparing duloxetine to placebo found duloxetine to be efficacious and tolerable for chronic pain associated with OA. Again it was noted that a higher number of patients in the duloxetine group withdrew due to adverse effects. 12 Localized/injectable therapy Intra-articular (IA) corticosteroids may be used to manage acute pain and localized inflammation associated with OA. [13] [14] [15] [16] Guidelines recommend the use of IA corticosteroids for OA pain that is unresponsive to acetaminophen and NSAIDs. The majority of evidence to support the use of this treatment is found in OA of the knee. Studies have found clinically significant shortterm decreases in knee pain 2 to 3 weeks postinjection. For a longer duration of pain relief, other treatment options should be considered. 12 There is little evidence to support the use of IA corticosteroids in the hand and hip. 13 Rheumatologists, using radiographic guidance, where appropriate, may provide injections to these joints for certain patients. As a general rule, the number of injections is limited to 3 or 4 for a single joint per year.
The role of hyaluronic acid injections in the management of OA is uncertain. 12, 13 Metaanalyses investigating the efficacy and safety of these agents have found inconsistent and conflicting results. 12 
Oral steroids
Oral steroids are not routinely used or recommended for management of OA. 12, 13 Monitoring Details on monitoring for efficacy and safety are provided in Tables 2 and 3 . • • Blood pressure should be measured at baseline and then every 2 to 4 weeks for 1 to 2 months. • • Those with uncontrolled hypertension or taking antihypertensives require more frequent monitoring (i.e., every 1-2 weeks for 1-2 months). • • Avoid concurrent use of more than 1 NSAID product when possible; the only exception is for patients taking low-dose aspirin for cardiovascular protection.
ACEI, angiotensin-converting enzyme inhibitor; CrCl, creatinine clearance; INR, international normalized ratio; NSAID, nonsteroidal antiinflammatory drug; SCr, serum creatinine.
PRaCtiCeguideLiNes

Conclusion
For a number of patients with OA, the combination of nonpharmacological measures with optimal acetaminophen or NSAID therapy provides adequate pain relief and functional improvement. OA is a common chronic condition in Canada, with dramatic increases in incidence on the horizon as our population ages. Pharmacists have the resources, the skills and the opportunity to become leaders in OA care and improve the lives of those affected by the condition. We believe these guidelines will be a valuable resource to pharmacists, as they highlight the most relevant aspects of OA management to help them care for their patients.■
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